AdnaGen AG, a privately-held biotechnology research and development company, is engaged in the the development of innovative tumor diagnostics by utilizing its proprietary technology for the detection and analysis of rare cells. The company's product line includes AdnaTest ColonCancer and AdnaTest BreastCancer products used for the detection and treatment of breast and colon cancer cells in human blood. The company is headquartered in Langenhagen, Germany. In January 2009, Sysmex Europe GmbH and AdnaGen AG entered into a distribution agreement for the detection of circulating tumor cells in all current and future AdnaGen products

The AdnaGen AG - Medical Equipment - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.

Scope

- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.

Reasons to buy

- A quick "one-stop-shop" to understand the company.
- Support sales activities by understanding your customers’ businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors’ business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.